Measles, mumps and rubella (MMR) vaccine-induced long-term immunity was studied in 30 children with bone marrow transplants (BMT). Immunity at baseline for MMR was 13.3, 33.3 and 66.6%, respectively. MMR vaccination failed to induce adequate and persistent responses to measles and mumps; seropositivity at 1 and 12 months for measles was 26.6 and 23.3% and for mumps 46.6 and 36.6%, respectively. In contrast, 27 of 30 children with a BMT were immune to rubella 1 month after immunization and retained protective antibody levels at 12 months. The MMR-induced anamnestic responses to rubella among all responders were associated with the production of high avidity antibodies. We conclude that a single dose of MMR given at 2 years after BMT induces suboptimal and short-lived immune responses to measles and mumps; a second dose should be recommended for paediatric BMT recipients.
Immunization against measles, mumps and rubella (MMR) is recommended for all children receiving bone marrow transplants (BMT) because most long-term BMT survivors become seronegative to these antigens. 1 MMR-induced immunity is long lasting among healthy subjects; 2 however, during a measles epidemic, 70% of the BMT recipients who had been vaccinated earlier than 3 years were susceptible to measles 3 and long-term serologic surveillance after MMR was recommended.
To evaluate thoroughly if the currently recommended reimmunization schedule induces adequate and persistent immune responses in paediatric BMT recipients, we evaluated MMR immunogenicity and the kinetics of specific antibody concentrations up to 12 months after vaccination.
While vaccine-induced immunologic memory associated with the production of high avidity antibodies after revaccination is considered an additional surrogate of protective immunity, 4 we employed rubella antibody avidity to investigate the type of immune response to revaccination.
Study design
In all, 30 children (19 boys) were recruited from the Bone Marrow Transplantation Unit, 'Aghia Sophia' Children's Hospital, Athens, Greece. BMT indications included malignancy (n ¼ 15), b-thalassemia (n ¼ 13) and immunodeficiency (n ¼ 2). BMT was autologous in six children and allogeneic in 24; four children had received a graft from matched unrelated donors. Patients' characteristics are shown in Table 1 . No children were on immunosuppressive therapy, intravenous immunoglobulin replacement therapy or had chronic graft-versus-host disease during the study period. All children had received one dose of MMR, as part of their childhood immunization or had experienced natural measles (n ¼ 3), mumps (n ¼ 3) or rubella infection (n ¼ 3) before BMT.
A single subcutaneous dose of MMR (0.5 ml MMR II; Merck-Sharp and Dohme, West Point, PA, USA) was offered to all subjects; guardians were instructed to report any side effects from vaccination. Blood samples were collected before and 1 and 12 months after vaccination. Serum samples were separated, frozen and stored (À201C) until tested.
Measles and mumps IgG antibodies were tested by a modification of the NOVUM measles/mumps virus IgG ELISA test kits (Novum Diagnostica GMBH, Germany) and rubella by Imx Rubella IgG2.0 antibody assay (Abbott Laboratories, Chicago, IL, USA). Antibody levels exceeding a cutoff value of 10 IU/ml were interpreted as representing immunity.
Rubella IgG avidity assay was performed in all rubella IgG-positive sera by an elution ELISA using a washing step with urea (BDH, Laboratory Supplies, Poole, UK) as described previously. 5 Avidity values above 60% were considered as indicative of an anamnestic immune response.
Continuous measures were analyzed by the Wilcoxon's signed-rank test and categorical variables by the w 2 test. Response to vaccination was defined as an increase in antibody levels above the protective threshold. Univariate analysis and multivariate logistic regressions examined candidate predictors of seropositivity at baseline and response at 1 and 12 months (age, BMT type, diagnosis, time of vaccination, CD3 (T-cell) and CD19 (B-cell) counts, CD4:CD8 ratio, patient's and donor's vaccination history (time of vaccination before transplant and number of doses)). Analyses were conducted using SPSS software, version 8.0 (SPSS, Chicago, USA). Statistical significance was defined as two-tailed Po0.05.
Results
At study entry, the median (range) age of the BMT recipients was 150 (24-228) months. The median time (range) from BMT to vaccination was 25 (15-85) months. The median (range) CD3 and CD19 counts and CD4:CD8 ratio were 1678/mm 3 (1250-2165), 768/mm 3 (494-853) and 1.6 (0.9-1.9), respectively.
There were no significant adverse reactions associated with vaccination.
In 11 (36.6%) of the 30 BMT recipients, baseline IgG antibody levels for all three vaccine antigens were undetectable. All subjects who had experienced natural measles, mumps or rubella disease retained their immunity after BMT.
All but four children had undetectable antibody levels to measles before vaccination. All subjects who were immune at baseline retained protective titers at 1 and 12 months after MMR; another four subjects responded to vaccination at 1 month, and all but one (23.3%) retained their immunity 12 months later. In all, 10 (33.3%) children were immune to mumps at baseline, four more children responded at 1 month (46.6%); however, only 11 (36.6%) children retained protective concentrations at 12 months. A total of 20 (66.6%) children were immune to rubella at baseline; four subjects had detectable but below the protective threshold antibody concentrations. All but three (90%) children responded to vaccination at 1 and 12 months. The kinetics of rubella antibody concentration revealed a significant increase in average IgG concentration at 1 and 12 months after vaccination among children who were seronegative at baseline (P ¼ 0.006 and 0.038 compared to baseline, at 1 and 12 months, respectively). In contrast, all immune at baseline children retained protective concentrations after vaccination, but antibody levels did not increase significantly during the follow-up period (P ¼ 0.3 and 0.7 compared to baseline, at 1 and 12 months, respectively).
There was no correlation between seropositivity at baseline for all three vaccine antigens, with age, time of vaccination, type of transplant, disease and vaccinee's and donor's vaccination history (P40.10 for all correlation coefficients). In addition, there was no association between response to vaccination with clinical, demographic and immunologic parameters of the vaccinee (P40.20).
As expected, all subjects who had retained their immunity to rubella after transplant had high avidity antibodies before and after revaccination. Interestingly, MMR induced anamnestic responses even in seronegative children at baseline, and the kinetics of concentration and avidity were similar in seropositive and seronegative subjects (Figure 1 ). 
Discussion
This is the first study to follow the kinetics of immune responses to MMR at 1 and 12 months after vaccination, in pediatric BMT recipients. According to our findings, 12 months after vaccination, more than half of our subjects had circulating antibodies to measles and mumps below a protective threshold, whereas nearly all of them were immune to rubella. Impaired long-term immunity to measles was associated with the lack of immediate seroconversion, whereas for mumps there were also secondary vaccine failures. Adult and pediatric BMT recipients show lower responses to MMR [6] [7] [8] than healthy subjects, where seroconversion rates are over 98% for all three antigens 9 and seropositivity above 90%, 2-4 years later. 10 King et al 8 reported that seropositivity to measles and mumps in vaccinated BMT children was 77 and 87%, respectively. The lower response observed in our study could be due to the earlier administration of the vaccine (25 vs 48 months after transplant). In King et al's study, the mean interval for nonresponders was 39 months compared to 56 for seroconverters. Impaired response to measles vaccine in the absence of profound immune abnormalities have been attributed to the persistence of humoral or cellular immunity. 11, 12 In our study, all nonresponders had undetectable circulating antibodies to measles at baseline; however, a remaining specific T-cell immunity that could have a negative effect on antibody production 13 cannot be excluded.
The high seroconversion rates to rubella is in accordance with previous reports 7, 8 and could be associated with the maintenance of memory after transplant, documented by the production of high avidity antibodies among all responders. Interestingly, seropositivity at baseline could not distinguish the subjects who had retained their memory, suggesting that even seronegative children could be partially protected. Evidence for the association of immunological memory and protection is coming from the observation that although measles is a severe disease in the immunocompromised, in BMT recipients who acquired measles during an epidemic and showed anamnestic immune responses during the acute phase, the disease had a benign course. 3 Immunologic memory could improve vaccine responses after BMT. However, the requirements for maintenance or transfer of B-memory cells in BMT recipients are not clear. For subjects undergoing allogeneic transplant, although donor's revaccination before harvesting could improve vaccine responses after transplant, 14 it probably does not overcome the need for routine reimmunization, because memory cells engraft with difficulty, they require long time to restore their function and decline quickly if they are not restimulated soon after transplant. 15 The type of antigen is important for the establishment of immunologic memory. Our study confirms the excellent antigenic characteristics of the RA27/3 rubella vaccine strain and is consistent with the observation that in contrast to measles and mumps, rubella outbreaks have never been reported in cohorts vaccinated with a single dose of MMR. History of natural MMR disease was also associated with seropositivity after transplant, suggesting that wild-type viruses induce memory more strongly than the attenuated viral vaccine antigens. Ljungman et al 1 have also reported that BMT patients who had measles remained seropositive longer than the vaccinated subjects.
As there is little natural boosting from circulating wild viruses, vaccine-induced immunity to MMR wanes over time. The major outbreaks could occur even among countries with extended MMR vaccination programs, placing susceptible BMT survivors at risk. Our findings suggest that a single dose of MMR given 2 years after transplant cannot induce long-lasting immunity for two of the three antigens, and support the policy that a second dose should be added in the recommended vaccination schedule.
